Biotech Distilled
Substack ↗
Subscribe
Subscribe
Substack ↗
About
Research
Areas
Modalities
Phases
Targets
Catalysts
Track record
Movers
The Lead Compound
Home
›
Targets
› JAK2V617F
JAK2V617F
(1 companies · 2 programs)
Companies with an active program directed at JAK2V617F.
Prelude Therapeutics Inc
PRLD
PRT12396
— Polycythemia Vera
Phase 1
PRT12396
— Myelofibrosis
Phase 1